General Information
Version
6.4
Revision date
2020-06-22
Product name
Decaborane(14)
CAS No.
17702-41-9
REACH No
A
Emergency telephone
+(31)-858880596
Icons in SDS
Company Information
company name
Merck Life Science N.V
e-mail address of the competent person responsible for the Safety Data Sheet
technischeservicebenelux@merckgroup.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H228, H301+H311, H315, H319, H330, H335
Hazard statements
Code
Statements
H228
Flammable solid
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Signal word
Danger
Hazard statements
H228 Flammable solid. H301 + H311 Toxic if swallowed or in contact with skin. H315 Causes skin irritation. H319 Causes serious eye irritation. H330 Fatal if inhaled. H335 May cause respiratory irritation.
Precautionary statements
P210 Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. P260 Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P280 Wear protective gloves/ protective clothing. P284 Wear respiratory protection. P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER/ doctor. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
Supplemental label elements
none
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher
2.1 Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 Flammable solids (Category 1), H228 Acute toxicity, Oral (Category 3), H301 Acute toxicity, Inhalation (Category 2), H330 Acute toxicity, Dermal (Category 3), H311 Skin irritation (Category 2), H315 Eye irritation (Category 2), H319 Specific target organ toxicity - single exposure (Category 3), Respiratory system, H335 For the full text of the H-Statements mentioned in this Section, see Section 16.
